STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

• Status: Active, not recruiting
• Trial end date: 2023-10-11
• Target enrollment: 0
• Participant gender: All

Summary

This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins"

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborators: Brigham and Women's Hospital; Dana-Farber Cancer Institute
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• > 18 years of age

• All patients with newly diagnosed NHL and HL

• Scheduled to receive anthracycline-based therapy

Exclusion Criteria:

• Statin use or Statin use is indicated based on guidelines

• Pregnancy or breastfeeding

• Unable to provide informed consent

• Unexplained persistent elevation of transaminases (>3 times upper limits of normal)

• Concomitant use of cyclosporine

• Renal failure: estimated glomerular filtration <45 mL/min/1.73 m2

• Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular clip

• LVEF of <50% at baseline